Immunogenicity and safety of COVID-19 booster vaccination: A population-based clinical trial to identify the best vaccination strategy

被引：2

作者：

Sieghart, Daniela ^{[1
]}

Hana, Claudia A. ^{[1
]}

Durrschmid, Caroline ^{[1
]}

Heinz, Leonhard X. ^{[1
]}

Haslacher, Helmuth ^{[2
]}

Zlesak, Markus ^{[1
]}

Piccini, Giulia ^{[3
]}

Manenti, Alessandro ^{[3
]}

Montomoli, Emanuele ^{[3
,8
]}

Jorda, Anselm ^{[4
]}

Fedrizzi, Clemens ^{[4
]}

Hasenoehrl, Timothy ^{[5
]}

Zdravkovic, Andrej ^{[5
]}

Anderle, Karolina ^{[4
]}

Wiedermann, Ursula ^{[6
]}

Drapalik, Susanne ^{[7
]}

Steinbrecher, Helmut ^{[7
]}

Bergmann, Felix ^{[4
]}

Firbas, Christa ^{[5
]}

Jordakieva, Galateja ^{[5
]}

Wagner, Barbara ^{[5
]}

Leonardi, Margherita ^{[3
]}

Pierleoni, Giulio ^{[3
]}

Ballini, Matilde ^{[3
]}

Benincasa, Linda ^{[3
]}

Marchi, Serena ^{[8
]}

Trombetta, Claudia ^{[8
]}

Perkmann, Thomas ^{[2
]}

Crevenna, Richard ^{[5
]}

Zeitlinger, Markus ^{[4
]}

Bonelli, Michael ^{[1
]}

Aletaha, Daniel ^{[1
]}

Radner, Helga ^{[1
]}

机构：

[1] Med Univ Vienna, Dept Internal Med 3, Div Rheumatol, Waehringer Guertel 18-20, A-1090 Vienna, Austria

[2] Med Univ Vienna, Dept Lab Med, Vienna, Austria

[3] Vismederi Srl, Siena, Italy

[4] Med Univ Vienna, Dept Clin Pharmacol, Vienna, Austria

[5] Med Univ Vienna, Dept Phys Med Rehabil & Occupat Med, Vienna, Austria

[6] Med Univ Vienna, Inst Spec Prophylaxis & Trop Med, Ctr Pathophysiol Infectiol & Immunol, Vienna, Austria

[7] Arbeiter Samariter Bund Wien, Vienna, Austria

[8] Univ Siena, Dept Mol & Dev Med, Siena, Italy

来源：

JOURNAL OF CLINICAL VIROLOGY | 2024年 / 173卷

关键词：

COVID-19; Vaccination; Immunogenicity; Immune response; Neutralizing antibodies; Population -based study; ANTIBODY;

D O I：

10.1016/j.jcv.2024.105661

中图分类号：

Q93 [微生物学];

学科分类号：

071005 ; 100705 ;

摘要：

Background: Various SARS-CoV-2 variants of concerns (VOCs) characterized by higher transmissibility and immune evasion have emerged. Despite reduced vaccine efficacy against VOCs, currently available vaccines provide protection. Population -based evidence on the humoral immune response after booster vaccination is crucial to guide future vaccination strategies and in preparation for imminent COVID-19 waves. Methods: This multicenter, population -based cohort study included 4697 individuals >= 18 years of age who received a booster vaccination. Antibody levels against SARS-CoV-2 receptor binding domain (RBD) and neutralizing antibodies against wild -type (WT) virus and Omicron variants were assessed at baseline (day of booster vaccination) and after four weeks. Safety was evaluated daily within the first week using a participantcompleted electronic diary. Antibody levels were compared across different vaccination strategies, taking into account individual host factors. Results: Our main model including 3838 participants revealed that individuals who received a booster with mRNA-1273 compared to BNT162b2 vaccine had a significantly higher increase (95 %CI) in anti-RBD-antibody levels (37,707 BAU/mL [34,575 -40,839] vs. 27,176 BAU/mL [26,265 -28,087]), and of neutralization levels against WT (1,681 [1490 -1872] vs. 1141 [1004 -1278] and Omicron variant (422 [369 -474] vs. 329 [284 -374]). Neutralizing antibody titres highly correlated with anti-RBD antibodies, with neutralizing capacity 4.4 fold higher against WT compared to Omicron. No differences in safety were found between the two booster vaccines. Conclusion: Our study underlines the superiority of a booster vaccination with mRNA-1273, independent of the primary vaccination and therefore provides guidance on the vaccination strategy.

引用

页数：8

共 25 条

[1]

Abrevaya J., 2002, ECONOMET REV, V21, P383, DOI DOI 10.1081/ETC-120015789

[2]

Andrews N, 2022, NEW ENGL J MED, V386, P1532, DOI [10.1056/NEJMoa2119451, 10.1016/S1473-3099(22)00309-7]

[3] Protection against Covid-19 by BNT162b2 Booster across Age Groups [J].

Bar-On, Yinon M. ;

Goldberg, Yair ;

Mandel, Micha ;

Bodenheimer, Omri ;

Freedman, Laurence ;

Alroy-Preis, Sharon ;

Ash, Nachman ;

Huppert, Amit ;

Milo, Ron .

NEW ENGLAND JOURNAL OF MEDICINE, 2021, 385 (26) :2421-2430

[4] Protection of BNT162b2 Vaccine Booster against Covid-19 in Israel [J].

Bar-On, Yinon M. ;

Goldberg, Yair ;

Mandel, Micha ;

Bodenheimer, Omri ;

Freedman, Laurence ;

Kalkstein, Nir ;

Mizrahi, Barak ;

Alroy-Preis, Sharon ;

Ash, Nachman ;

Milo, Ron ;

Huppert, Amit .

NEW ENGLAND JOURNAL OF MEDICINE, 2021, 385 (15) :1393-1400

[5] Chronic inhibition of cyclooxygenase-2 attenuates antibody responses against vaccinia infection [J].

Bernard, Matthew P. ;

Bancos, Simona ;

Chapman, Timothy J. ;

Ryan, Elizabeth P. ;

Treanor, John J. ;

Rose, Robert C. ;

Topham, David J. ;

Phipps, Richard P. .

VACCINE, 2010, 28 (05) :1363-1372

[6]

Cameron A.C., 2010, Microeconometrics using Stata

[7] Heterologous versus homologous COVID-19 booster vaccination in previous recipients of two doses of CoronaVac COVID-19 vaccine in Brazil (RHH-001): a phase 4, non-inferiority, single blind, randomised study [J].

Costa Clemens, Sue Ann ;

Weckx, Lily ;

Clemens, Ralf ;

Almeida Mendes, Ana Verena ;

Souza, Alessandra Ramos ;

Silveira, Mariana B., V ;

Farias da Guarda, Suzete Nascimento ;

de Nobrega, Maristela Miyamoto ;

de Moraes Pinto, Maria Isabel ;

Gonzalez, Isabela G. S. ;

Salvador, Natalia ;

Franco, Marilia Miranda ;

de Avila Mendonca, Renata Navis ;

Queiroz Oliveira, Isabelle Silva ;

de Freitas Souza, Bruno Solano ;

Fraga, Mayara ;

Aley, Parvinder ;

Bibi, Sagida ;

Cantrell, Liberty ;

Dejnirattisai, Wanwisa ;

Liu, Xinxue ;

Mongkolsapaya, Juthathip ;

Supasa, Piyada ;

Screaton, Gavin R. ;

Lambe, Teresa ;

Voysey, Merryn ;

Pollard, Andrew J. .

LANCET, 2022, 399 (10324) :521-529

[8] Evidence for antibody as a protective correlate for COVID-19 vaccines [J].

Earle, Kristen A. ;

Ambrosino, Donna M. ;

Fiore-Gartland, Andrew ;

Goldblatt, David ;

Gilbert, Peter B. ;

Siber, George R. ;

Dull, Peter ;

Plotkin, Stanley A. .

VACCINE, 2021, 39 (32) :4423-4428

[9]

European Centre for Disease Prevention and Control (ECDC), 2022, COUNTR OV REP WEEK 2

[10]

Federal Ministry Republic of Austria of Social Affairs H, Care and consumer protection. Covid-19 Impfungen: Anwendungsempfehlungen des Nationalen Impfgremiums

← 1 2 3 →